We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-64.00 | -0.60% | 10,678.00 | 10,688.00 | 10,690.00 | 10,780.00 | 10,674.00 | 10,756.00 | 1,773,970 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 27.83 | 165.72B |
Date | Subject | Author | Discuss |
---|---|---|---|
27/3/2024 15:46 | Much more like it today. Plenty of good news lately. | philanderer | |
21/3/2024 22:16 | You're a bit of a one trick pony aren't you! | mattboxy | |
21/3/2024 08:47 | Money moving to APH [LSE] , excellent profitable healthcare company | blackhorse23 | |
19/3/2024 08:50 | Wonder how many Fusion Pharm shareholders were relatively new and benefitted from the 97% premium to 18th March close! Bound to have been plenty of insider dealing stateside, probably in "Options" to leverage the benefit. Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2bn, a 97% premium to Fusion's closing market price of $10.64 on 18th March 2024 and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.37 before this announcement. | geckotheglorious | |
19/3/2024 07:51 | A billion dollar deal last week and a two billion dollar deal today….Mr Soriot is investing for the future….that is where the divi increase is being diverted to. | 1jat | |
04/3/2024 15:26 | They bought one in early phase development in November: hxxps://www.astrazen | andygibb101 | |
01/3/2024 13:14 | It's a shame Astra did not have the fat buster drug, Novo Nordisk and EJ Lily gone through the roof. | montyhedge | |
27/2/2024 08:15 | Astra has an IR day in May where they are expected to try to talk up their longer term growth potential | smcni1968 | |
21/2/2024 14:26 | Money moving to APH , excellent growth health care company | blackhorse23 | |
21/2/2024 10:55 | philanderer - a suggestion The link does work if you delete everything after "html" - otherwise it seems to stretch the page. | mirandaj | |
21/2/2024 00:19 | "The £135m man: That's how much Pascal Soriot has been paid in 12 years at AstraZeneca... with more to come" | philanderer | |
20/2/2024 09:46 | Berenberg cuts AstraZeneca price target to 12,000 (12,500) pence - 'buy' | philanderer | |
20/2/2024 00:23 | MARKET REPORT: Lung cancer drug gives AstraZeneca a shot in arm | philanderer | |
19/2/2024 15:03 | Hopefully the US investors will get this moving up tomorrow | smcni1968 | |
19/2/2024 10:09 | #987. Novo will need to use its new cash flows to diversify. | alphorn | |
19/2/2024 10:06 | Today's news good for the company and good for patients. | alphorn | |
14/2/2024 09:04 | Novo Nordisk the pharma to be in and Glaxo looking good. | montyhedge | |
12/2/2024 17:26 | Market report "...AstraZeneca shares came into the week on a three-day losing streak, including a more than 6% slide on the day it released annual results. "‘We think this presents a compelling entry point for a best-in-class company,’ analysts at Barclays said on Monday, however." sharesmagazine.co.uk | philanderer | |
12/2/2024 16:22 | Don't tell me you sold these to buy APH as well! If APH are so good you should follow your own advice and put all your eggs in that creaky basket. | mattboxy | |
12/2/2024 16:13 | Ex div on the 22nd, may pick up some before then. | chc15 | |
12/2/2024 15:48 | 24 month low for the shareprice. Chartwise, support at 8300p | philanderer | |
12/2/2024 11:50 | Blackhorse. No it isn't. Grow up. | tday | |
12/2/2024 11:37 | Money moving to APH | blackhorse23 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions